Myasthenia gravis (MG) is an autoimmune condition leading to extreme muscle weakness due to autoantibodies targeting the neuromuscular junctions. Here authors assign a critical role for platelets in amplifying the pro-inflammatory response in AChR+ immunotherapy-naïve MG (nMG) patients and thus contributing to disease pathology.